People · Operator
Named in public records as an officer, director or promoter · active 2014–2018 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Qualigen Therapeutics, Inc. | — | Biotechnology | Series A | $27.9M | $14.1M | 2014 |
Noah E. Doyle at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Noah E. Doyle on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Noah Doyle | 1 | 19 |
| Paul V. Maier | 1 | 6 |
| Matthew W. Foehr | 1 | 4 |
| Braeden Lichti | 1 | 4 |
| Graydon Bensler | 1 | 4 |
| Campbell Becher | 1 | 3 |
| Andrew Ritter | 1 | 3 |
| THOMAS ADAMEK | 1 | 2 |
| Ira Ritter | 1 | 2 |
| Ira E. Ritter | 1 | 2 |
| Kevin Richardson II | 1 | 2 |
| Michael D. Step | 1 | 1 |
| Thomas E. Adamek | 1 | 1 |
| Robert B. Lim | 1 | 1 |
| Cody B. Price | 1 | 1 |
| Robert Lim | 1 | 1 |
| Cody Price | 1 | 1 |
| John W. Beck | 1 | 1 |
| William M. Merino | 1 | 1 |
| Steven Markowitz | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.